Swedish Orphan Biovitrum (OTCMKTS:BIOVF) Rating Increased to Hold at Zacks Research

Swedish Orphan Biovitrum (OTCMKTS:BIOVF) was upgraded by analysts at Zacks Research to a “hold” rating in a research note issued to investors on Thursday,Zacks.com reports.

Several other equities research analysts have also recently issued reports on BIOVF. HC Wainwright assumed coverage on Swedish Orphan Biovitrum in a research note on Wednesday. They set a “buy” rating for the company. Danske cut Swedish Orphan Biovitrum to a “hold” rating in a research note on Thursday, February 19th. Barclays reissued an “overweight” rating on shares of Swedish Orphan Biovitrum in a research note on Tuesday, February 24th. Finally, BNP Paribas Exane raised Swedish Orphan Biovitrum to an “outperform” rating in a research note on Tuesday, February 10th. Four equities research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy”.

Swedish Orphan Biovitrum Price Performance

Swedish Orphan Biovitrum stock opened at $47.48 on Thursday. Swedish Orphan Biovitrum has a 12-month low of $27.06 and a 12-month high of $47.48. The stock has a market cap of $16.90 billion, a P/E ratio of 158.25 and a beta of 0.34. The company has a 50-day moving average price of $40.85 and a 200 day moving average price of $37.43. The company has a current ratio of 0.90, a quick ratio of 0.59 and a debt-to-equity ratio of 0.14.

Swedish Orphan Biovitrum (OTCMKTS:BIOVF) last released its quarterly earnings data on Tuesday, April 28th. The company reported $0.45 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.38 by $0.07. Swedish Orphan Biovitrum had a net margin of 3.37% and a return on equity of 17.23%. The firm had revenue of $755.76 million during the quarter, compared to analysts’ expectations of $749.76 million. Sell-side analysts anticipate that Swedish Orphan Biovitrum will post 2.26 earnings per share for the current year.

Key Swedish Orphan Biovitrum News

Here are the key news stories impacting Swedish Orphan Biovitrum this week:

• Positive Sentiment: HC Wainwright maintained a Buy rating on Swedish Orphan Biovitrum and projected rising earnings through 2026 and 2027, including $2.26 EPS for FY2026 and $3.49 EPS for FY2027, which may reinforce investor confidence. Swedish Orphan Biovitrum stock page
• Neutral Sentiment: The new report mainly updated quarterly and annual EPS estimates for multiple future periods, but it did not include a fresh business update, catalyst, or management guidance change. Swedish Orphan Biovitrum stock page

About Swedish Orphan Biovitrum

Swedish Orphan Biovitrum AB (publ), commonly known as Sobi, is a Stockholm‐based biopharmaceutical company specializing in the development, manufacturing and commercialization of treatments for rare diseases. Formed in 2010 through the merger of Swedish Orphan International AB (established 1985) and Biovitrum AB, the company focuses on high‐value therapies in hematology, immunology, oncology and genetic/metabolic disorders. Sobi’s strategy centers on building a global specialty care portfolio by in‐licensing, acquiring and internally developing innovative products aimed at small patient populations with significant unmet needs.

The company’s marketed portfolio includes recombinant clotting factor therapies such as Elocta (rFVIIIFc) and Alprolix (rFIXFc) for hemophilia A and B, respectively; Ruconest, a recombinant human C1 esterase inhibitor for hereditary angioedema; and Kineret (anakinra) for certain auto‐inflammatory conditions.